PharmaCyte Biotech Inc (PMCB)

[PINKribbon]

New investors, many times it’s been said that PharmaCyte’s PI, world renowned oncologist, Dr. Manuel Hidalgo, never “presents” PharmaCyte’s CiaB PC therapy as being an “emerging” therapy in pancreatic cancer medicine.

Well, that’s simply because he needs to see consistent findings or evidence first.

It has NOTHING to do with his credibility.

To be more precise, this is exactly how Dr. Hidalgo, explains the need for a CT in a nutshell....

“The primary goal of the study is to determine the efficacy of this approach, compared to a standard of care treatment, in controlling LAPC. If this endpoint is met, the technology will be validated as a therapeutic option in patients with LAPC.”

There you have it...cut and dry. Without that “validation” Dr. Hidalgo cannot determine whether or not PharmaCyte’s CiaB PC therapy is an “emerging” treatment.

IND submission underway!

Stay tuned!

Patience :)


Sir GENIUS rocks!!!
Go Team PharmaCyte!!!